Despite a great amount of studies, no ideal marker has been found for urologic tumours. The controversial aspects regarding the clinical use of prostatic cancer markers, especially PSA, are focused on without going into detail, although some surveys are presented. The same approach is followed for the problems regarding germ cell tumours of the testis; a survey is presented as well. Lastly bladder and kidney tumours are taken into consideration, for which, despite the efforts of the most sophisticated research studies, a moving clinically-usable marker hasn't been isolated up to now.
4° International Symposium on recent advances in Urological cancer diagnosis and treatment. Paris, 22-23 giugno 1994.
3.
HulandH., SchneiderA.W., HulandE.: Sensitivity of urinary quantitative immunocytology with monoclonal antibody 486P3/12 in 241 unselected patients with bladder carcinoma. J. Urol., 145: 495–497, 1991.
4.
EpelbaumR., MoskovitzB., SegaiR., MekoriT., NativO., ShalitinC.: The significance of a 21kDa protein serum levels in the follow-up of patients with renal cell carcinoma after radicai nephrectomy. Ecco, 7: 1305, 1992.
5.
BlayJ.Y., NegrierS., CombaretV., GoillotE., MercatelloA., RavaudA., TouraniJ.M., MoskovtchenkoJ.F., PhilipT., FavrotM.: IL6 and metastatic clear cell renal carcinoma: a prognosis factor for response and survival after IL2 therapy. ASCO, 11: 217, 684.
